FLT3 ligand administration inhibits tumor growth in murine melanoma and lymphoma

Successful treatment of melanoma and lymphoma may result from the induction of specific antitumor immunity. Dendritic cells (DCs) are powerful antigen-presenting cells and show a remarkable capacity to stimulate antigen-specific T-cell responses. Administration of FLT3 ligand (FL) results in a rever...

Full description

Saved in:

Bibliographic Details
Published in:	Cancer research (Chicago, Ill.) Vol. 58; no. 3; pp. 380 - 383
Main Authors:	ESCHE, C, SUBBOTIN, V. M, MALISZEWSKI, C, LOTZE, M. T, SHURIN, M. R
Format:	Journal Article
Language:	English
Published:	Philadelphia, PA American Association for Cancer Research 01-02-1998
Subjects:	Animals Antineoplastic agents Biological and medical sciences Dendritic Cells - drug effects Dendritic Cells - immunology Drug Screening Assays, Antitumor Immunity, Cellular - drug effects Immunologic Factors - pharmacology Immunologic Factors - therapeutic use Immunotherapy Lymphoma, T-Cell - immunology Lymphoma, T-Cell - therapy Male Medical sciences Melanoma, Experimental - immunology Melanoma, Experimental - therapy Membrane Proteins - pharmacology Membrane Proteins - therapeutic use Mice Mice, Inbred C57BL Neoplasm Transplantation Pharmacology. Drug treatments Recombinant Proteins - pharmacology Recombinant Proteins - therapeutic use Skin Neoplasms - immunology Skin Neoplasms - therapy T-Lymphocytes - immunology Tumor Cells, Cultured Dendritic cell Flt3 ligand Rodentia Malignant hemopathy Malignant tumor Vertebrata Mammalia Treatment Mouse Lymphoproliferative syndrome Animal Immunotherapy Established cell line Malignant melanoma Malignant lymphoma Subcutaneous administration Tumor cell
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!